A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Lenabasum (Primary)
- Indications Dermatomyositis
- Focus Registrational; Therapeutic Use
- Acronyms DETERMINE
- Sponsors Corbus Pharmaceuticals
- 07 Nov 2019 According to a Corbus Pharmaceuticals media release, 68-week safety and efficacy data from the open-label extension study will presented at the American College of Rheumatology (ACR) 2019 Annual Meeting.
- 08 Aug 2019 According to an Corbus Pharmaceuticals media release, top-line data from this study is expected in 2021.
- 28 May 2019 According to a Corbus Pharmaceuticals media release, design of the study will be presented at the European League Against Rheumatism (EULAR) 2019 Annual Meeting.